Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fibromuscular Dysplasia.

David P Slovut1, Jeffrey W Olin

  • 1The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine,One Gustave L. Levy Place, Box 1033,New York,NY 10029-6574,USA. jeffrey.olin@msnyuhealth.org.

Current Treatment Options in Cardiovascular Medicine
|June 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research priorities for peripheral artery disease: A statement from the Society for Vascular Medicine.

Vascular medicine (London, England)·2025
Same author

Integrative gene regulatory network analysis discloses key driver genes of fibromuscular dysplasia.

Nature cardiovascular research·2024
Same author

Paclitaxel-Mortality Risk Hypothesis Debunked: What We Learned and How It Will Change Future Clinical Trials.

Journal of the American College of Cardiology·2024
Same author

The Ongoing Odyssey of Renal Denervation.

Journal of the American College of Cardiology·2023
Same author

Genome-wide association meta-analysis of spontaneous coronary artery dissection identifies risk variants and genes related to artery integrity and tissue-mediated coagulation.

Nature genetics·2023
Same author

ACC/AHA Aortic Disease Guidelines: What Was Simple Is Now Complex-Moving to Multidisciplinary Teams, Specialized Centers.

Journal of the American College of Cardiology·2022

Fibromuscular dysplasia (FMD) commonly causes hypertension and stroke. Treatment involves angioplasty for renal artery FMD and antiplatelet agents or angioplasty for cerebrovascular FMD.

Area of Science:

  • Vascular Medicine
  • Neurology
  • Nephrology

Background:

  • Fibromuscular dysplasia (FMD) is a rare non-atherosclerotic vascular disease.
  • Common clinical manifestations include hypertension from renal artery FMD and stroke from cerebrovascular FMD.

Purpose of the Study:

  • To outline the primary treatment strategies for patients diagnosed with fibromuscular dysplasia.
  • To provide guidance on managing hypertension and cerebrovascular events associated with FMD.

Main Methods:

  • Review of current clinical guidelines and therapeutic recommendations for FMD.
  • Analysis of treatment outcomes for angioplasty and pharmacotherapy in FMD patients.

Main Results:

  • Primary angioplasty is recommended for renal artery FMD with hypertension, aiming for hypertension cure.

Related Experiment Videos

  • If hypertension persists post-angioplasty, antihypertensive medications are advised.
  • Antiplatelet agents are the primary therapy for cerebrovascular FMD.
  • Percutaneous angioplasty is the preferred treatment for symptomatic cerebrovascular FMD.

    • Conclusions:

    • Timely and appropriate intervention can significantly improve outcomes for FMD patients.
    • Management strategies should be tailored to the specific arterial territory involved.
    • Further research may elucidate optimal long-term management for complex FMD cases.